AAREYDRUGS vs WINDLAS: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Windlas Biotech Ltd

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Windlas Biotech Ltd is the larger company by market capitalisation. Aarey Drugs & Pharmaceuticals Limited shows faster revenue growth, while Windlas Biotech Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 3 of 13 scored metrics and WINDLAS on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WINDLAS is the larger company
₹1,806 Cr vs ₹221 Cr
P/E Ratio
WINDLAS has a lower P/E
28x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 3.2x
EPS
WINDLAS has higher earnings per share
₹31.5 vs ₹1.47
Dividend Yield
WINDLAS has a higher dividend yield
0.72% vs 0%
Revenue Growth (TTM YoY)
AAREYDRUGS has faster revenue growth
19.8% vs 17.7%
EPS Growth (TTM YoY)
WINDLAS has faster EPS growth
-2.6% vs -41.05%
Qtr Sales Growth
WINDLAS has stronger quarterly sales growth
17.7% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSWINDLAS
Live Price₹90.51₹871
Day Change-4.92%-1.08%
Volume2.2 L33,295
52-Week High₹96₹1,097.9
52-Week Low₹50.31₹697.4
Distance from 52W High-5.72%-20.67%

Valuation

MetricAAREYDRUGSWINDLAS
Market Cap₹221 Cr₹1,806 Cr
P/E Ratio55.36x28x
P/B Ratio1.46x3.2x
EPS₹1.47₹31.5
Book Value₹48.67₹275
Dividend Yield0%0.72%

Growth

MetricAAREYDRUGSWINDLAS
Revenue Growth (TTM YoY)19.8%17.7%
EPS Growth (TTM YoY)-41.05%-2.6%
Qtr Sales Growth0%17.7%
Qtr Profit Growth0%-1.78%

Profitability & Leverage

MetricAAREYDRUGSWINDLAS
ROE2.64%12.2%
ROCE6%15.9%
Net Margin0.84%7.35%
Operating Margin2.21%11.6%
Debt to Equity0.33x0.06x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSWINDLAS
Promoter Holding37.71% 1.35 pp63.31% 1.41 pp
FII Holding4.18% 0.32 pp2.04% 1.44 pp
DII Holding1.62% 1.62 pp9.84% 1.97 pp
Public Holding56.49% 0.6 pp24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.